IP Library › Granted Patent US 10,471,028
Granted Patent B2
US 10,471,028 · App. 15/317,811 · Granted Nov 12, 2019

Small molecule efflux pump inhibitors

Inventors: Paul M. Dunman (Pittsford, NY); Catlyn E. Blanchard (Rochester, NY)
Assignee: UNIVERSITY OF ROCHESTER
A61K31/18A61K31/00A61K31/15A61K31/166A61K31/216A61K31/235A61K31/352A61K31/357A61K31/402A61K31/4155A61K31/427A61K31/428A61K31/437A61K31/438A61K31/4422A61K31/63A61K31/635A61K31/65
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,471,028
App. No.
15/317,811
Granted
Nov 12, 2019
Kind
B2
Abstract

Small molecule efflux pump inhibitors are provided, as well as methods for their use in treating infections. Also provided herein are methods of using the small molecule efflux pump inhibitors to restore the antibiotic susceptibility of microbes.

Claims (10)

1. A method for treating a microbial infection in a subject, comprising administering to the subject an effective amount of an efflux pump inhibitor of the following formula:

and

an antimicrobial agent.

2. The method of claim 1 , further comprising selecting a subject infected with a microbe that is resistant to the antimicrobial agent.

3. The method of claim 2 , wherein the resistance is mediated by an efflux pump.

4. The method of claim 1 , wherein the microbial infection is a bacterial infection.

5. The method of claim 4 , wherein the bacterial infection is a gram-negative bacterial infection.

6. The method of claim 4 , wherein the bacterial infection is a gram-positive bacterial infection.

7. The method of claim 1 , wherein the antimicrobial agent is selected from the group consisting of minocycline, ciprofloxacin, levofloxacin, nalidixic acid, amikacin, gentamycin, kanamycin, meropenem, ceftriaxone, erythromycin, colistin polymxin B, sulfamethoxazole, tigecycline, tobramycin, and trimethoprim.

8. The method of claim 1 , wherein the efflux pump inhibitor and the antimicrobial agent are administered sequentially or simultaneously.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2017
From: DUNMAN, PAUL M.; BLANCHARD, CATLYN E.
To: UNIVERSITY OF ROCHESTER
Reel/Frame 041526/0884 →
Continuity (2)
Provisional Application 62011613 · Jun 13, 2014
Related Publication 20170100414A1 · Apr 13, 2017